The amount of injected ¹⁷⁷Lu-octreotate strongly influences biodistribution and dosimetry in C57BL/6N mice

References

• Forssell-Aronsson E, Schüler E, Ahlman H. Advances in the diagnostic imaging of pheochromocytomas. Rep Med Imaging 2011;4:19–37.
   Google Scholar
• van Essen M, Sundin A, Krenning EP, Kwekkeboom DJ. Neuroendocrine tumours: The role of imaging for diagnosis and therapy. Nat Rev Endocrinol 2014;10:102–14.
   PubMed Web of Science ®Google Scholar
• Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273–82.
   PubMedGoogle Scholar
• Reubi JC, Waser B, Schaer JC, Laissue JA. Somatostatin receptor sst1-sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001;28:836–46.
   PubMedGoogle Scholar
• Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: Toxicity, efficacy, and survival. J Clin Oncol 2008;26:2124–30.
   PubMed Web of Science ®Google Scholar
• Khan S, Krenning EP, van Essen M, Kam BL, Teunissen JJ, Kwekkeboom DJ. Quality of life in 265 patients with gastroenteropancreatic or bronchial neuroendocrine tumors treated with [177Lu-DOTA0,Tyr3]octreotate. J Nucl Med 2011;52:1361–8.
   PubMed Web of Science ®Google Scholar
• Van Essen M, Krenning EP, De Jong M, Valkema R, Kwekkeboom DJ. Peptide receptor radionuclide therapy with radiolabelled somatostatin analogues in patients with somatostatin receptor positive tumours. Acta Oncol 2007; 46:723–34.
   PubMed Web of Science ®Google Scholar
• Rolleman EJ, Melis M, Valkema R, Boerman OC, Krenning EP, de Jong M. Kidney protection during peptide receptor radionuclide therapy with somatostatin analogues. Eur J Nucl Med Mol Imaging 2010;37:1018–31.
   PubMed Web of Science ®Google Scholar
• Forssell-Aronsson E, Spetz J, Ahlman H. Radionuclide therapy via SSTR: Future aspects from experimental animal studies. Neuroendocrinology 2013;97:86–98.
   PubMed Web of Science ®Google Scholar
• Dalmo J, Rudqvist N, Spetz J, Laverman P, Nilsson O, Ahlman H, et al. Biodistribution of 177Lu-octreotate and 111In-minigastrin in female nude mice transplanted with human medullary thyroid carcinoma GOT2. Oncol Rep 2012;27:174–81.
   PubMed Web of Science ®Google Scholar
• Bernhardt P, Kolby L, Johanson V, Nilsson O, Ahlman H, Forssell-Aronsson E. Biodistribution of 111in-DTPA- D-Phe1-octreotide in tumor-bearing nude mice: Influence of amount injected and route of administration. Nucl Med Biol 2003;30:253–60.
   PubMed Web of Science ®Google Scholar
• Sabet A, Nagarajah J, Dogan AS, Biersack HJ, Sabet A, Guhlke S, et al. Does PRRT with standard activities of 177Lu-octreotate really achieve relevant somatostatin receptor saturation in target tumor lesions?: Insights from intra-therapeutic receptor imaging in patients with metastatic gastroenteropancreatic neuroendocrine tumors. EJNMMI Res 2013;3:82.
   PubMed Web of Science ®Google Scholar
• Andersson P, Forssell-Aronsson E, Grétarsdóttir J, Johansson V, Wängberg B, Nilsson O, et al. Biokinetics and dosimetry after repeated injections of 111In-DTPA- D-Phe1-octreotide. In: Sixth International Radiopharmaceutical Dosimetry Symposium, Gatlinburg, Tennessee. 1999; 1:127–36.
   Google Scholar
• Schmitt A, Bernhardt P, Nilsson O, Ahlman H, Kolby L, Schmitt J, et al. Biodistribution and dosimetry of 177Lu-labeled [DOTA0,Tyr3]octreotate in male nude mice with human small cell lung cancer. Cancer Biother Radiopharm 2003;18:593–9.
   PubMed Web of Science ®Google Scholar
• de Araujo EB, Caldeira Filho JS, Nagamati LT, Muramoto E, Colturato MT, Couto RM, et al. A comparative study of 131I and 177Lu labeled somatostatin analogues for therapy of neuroendocrine tumours. Appl Radiat Isot 2009;67:227–33.
   PubMed Web of Science ®Google Scholar
• Sward C, Bernhardt P, Johanson V, Schmitt A, Ahlman H, Stridsberg M, et al. Comparison of [177Lu-DOTA0,Tyr3]-octreotate and [177Lu-DOTA0,Tyr3]-octreotide for receptor-mediated radiation therapy of the xenografted human midgut carcinoid tumor GOT1. Cancer Biother Radiopharm 2008;23:114–20.
   PubMed Web of Science ®Google Scholar
• Schuler E, Rudqvist N, Parris TZ, Langen B, Helou K, Forssell-Aronsson E. Transcriptional response of kidney tissue after (177)Lu-octreotate administration in mice. Nucl Med Biol 2014;41:238–47.
   PubMed Web of Science ®Google Scholar
• Schuler E, Rudqvist N, Parris TZ, Langen B, Spetz J, Helou K, et al. Time- and dose rate-related effects of internal Lu exposure on gene expression in mouse kidney tissue. Nucl Med Biol 2014;41:825–32.
   PubMed Web of Science ®Google Scholar
• Amundson SA, Lee RA, Koch-Paiz CA, Bittner ML, Meltzer P, Trent JM, et al. Differential responses of stress genes to low dose-rate gamma irradiation. Mol Cancer Res 2003;1:445–52.
   PubMed Web of Science ®Google Scholar
• Loevinger R, Budinger TF, Watson EE. MIRD primer for absorbed dose calculations. Michigan: Society of Nuclear Medicine; 1988.
   Google Scholar
• Uusijarvi H, Bernhardt P, Rosch F, Maecke HR, Forssell-Aronsson E. Electron- and positron-emitting radiolanthanides for therapy: Aspects of dosimetry and production. J Nucl Med 2006;47:807–14.
   PubMed Web of Science ®Google Scholar
• Melis M, Krenning EP, Bernard BF, Barone R, Visser TJ, de Jong M. Localisation and mechanism of renal retention of radiolabelled somatostatin analogues. Eur J Nucl Med Mol Imaging 2005;32:1136–43.
   PubMed Web of Science ®Google Scholar
• Melis M, Krenning EP, Bernard BF, de Visser M, Rolleman E, de Jong M. Renal uptake and retention of radiolabeled somatostatin, bombesin, neurotensin, minigastrin and CCK analogues: species and gender differences. Nucl Med Biol 2007;34:633–41.
   PubMed Web of Science ®Google Scholar
• Miller WH, Hartmann-Siantar C, Fisher D, Descalle MA, Daly T, Lehmann J, et al. Evaluation of beta-absorbed fractions in a mouse model for 90Y, 188Re, 166Ho, 149Pm, 64Cu, and 177Lu radionuclides. Cancer Biother Radiopharm 2005;20:436–49.
   PubMed Web of Science ®Google Scholar
• Kolby L, Bernhardt P, Johanson V, Schmitt A, Ahlman H, Forssell-Aronsson E, et al. Successful receptor-mediated radiation therapy of xenografted human midgut carcinoid tumour. Br J Cancer 2005;93:1144–51.
   PubMed Web of Science ®Google Scholar
• Kletting P, Muller B, Erentok B, Schmaljohann J, Behrendt FF, Reske SN, et al. Differences in predicted and actually absorbed doses in peptide receptor radionuclide therapy. Med Phys 2012;39:5708–17.
   PubMed Web of Science ®Google Scholar
• Velikyan I, Sundin A, Eriksson B, Lundqvist H, Sorensen J, Bergstrom M, et al. In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours – impact of peptide mass. Nucl Med Biol 2010;37:265–75.
   PubMed Web of Science ®Google Scholar
• Wessels BW, Bolch WE, Bouchet LG, Breitz HB, Denardo GL, Meredith RF, et al. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: A multiinstitutional comparison. J Nucl Med 2004;45: 1725–33.
   PubMed Web of Science ®Google Scholar
• Cremonesi M, Ferrari M, Zoboli S, Chinol M, Stabin MG, Orsi F, et al. Biokinetics and dosimetry in patients administered with (111)In-DOTA-Tyr(3)-octreotide: Implications for internal radiotherapy with (90)Y-DOTATOC. Eur J Nucl Med 1999;26:877–86.
   PubMedGoogle Scholar
• Forrer F, Krenning EP, Kooij PP, Bernard BF, Konijnenberg M, Bakker WH, et al. Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate. Eur J Nucl Med Mol Imaging 2009;36:1138–46.
   PubMed Web of Science ®Google Scholar
• Forssell-Aronsson E, Bernhardt P, Nilsson O, Tisell LE, Wangberg B, Ahlman H. Biodistribution data from 100 patients i.v. injected with 111In-DTPA-D-Phe1-octreotide. Acta Oncol 2004;43:436–42.
   PubMed Web of Science ®Google Scholar
• Deblonde GJ, Sturzbecher-Hoehne M, Mason AB, Abergel RJ. Receptor recognition of transferrin bound to lanthanides and actinides: A discriminating step in cellular acquisition of f-block metals. Metallomics 2013;5:619–26.
   PubMed Web of Science ®Google Scholar